Cargando…

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease

BACKGROUND/AIMS: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patients with Crohn’s disease (CD) are rare, particularly for Asian patients. We compared the key clinical outcomes (surgery, hospitalization, and corticosteroid use) of use of these two drugs in biolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Yoon Suk, Han, Minkyung, Park, Sohee, Cheon, Jae Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817934/ https://www.ncbi.nlm.nih.gov/pubmed/32839359 http://dx.doi.org/10.5009/gnl19377

Ejemplares similares

Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
por: Han, Minkyung, et al.
Publicado: (2020)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
por: Lee, Yong Il, et al.
Publicado: (2021)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
por: Sohn, Il Woong, et al.
Publicado: (2016)

Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study
por: Jung, Yoon Suk, et al.
Publicado: (2020)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
por: Kaniewska, Magdalena, et al.
Publicado: (2020)

Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
por: Song, Won Jae, et al.
Publicado: (2016)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Cancer risk in Korean patients with Behçet’s disease: A nationwide population-based study
por: Jung, Yoon Suk, et al.
Publicado: (2017)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Corrigendum to: Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
Publicado: (2021)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
por: Ji, Cheng-Chun, et al.
Publicado: (2017)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
por: Orts, Beatriz, et al.
Publicado: (2022)

Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
por: Yang, Hua-Hua, et al.
Publicado: (2022)

Infliximab response associates with radiologic findings in bio-naïve Crohn’s disease
por: Yueying, Chen, et al.
Publicado: (2023)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
por: Kim, Nam Hee, et al.
Publicado: (2014)

Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
por: Mizoshita, Tsutomu, et al.
Publicado: (2014)

Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn’s Disease: A Retrospective Claims Database Analysis
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
por: Park, Sang Hyoung, et al.
Publicado: (2022)

Arquitectura del renacimiento en España, 1488-1599 /
por: Nieto Alcaide, Víctor Manuel
Publicado: (1997)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019)

Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study
por: PREDA, C., et al.
Publicado: (2016)

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
por: Gu, Bonita, et al.
Publicado: (2022)

Comparing adalimumab and infliximab in the prevention of postoperative recurrence of Crohn’s disease: a systematic review and meta-analysis
por: Gangwani, Manesh Kumar, et al.
Publicado: (2023)

Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study
por: Han, Minkyung, et al.
Publicado: (2020)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy
por: Mizoshita, Tsutomu, et al.
Publicado: (2017)

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn’s Disease Treated with Adalimumab or Infliximab
por: Yokoyama, Kaoru, et al.
Publicado: (2016)

Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation
por: Bronsky, Jiri, et al.
Publicado: (2022)

Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature
por: Verma, Sanam, et al.
Publicado: (2013)

Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cgh4g89bkt68gfrblcva9jv1s6